Stratification of the risk of serious allergic cutaneous reactions with therapeutic management of trigeminal neuralgia.
Patients with the HLA-B*1502 allele have a high risk of serious allergic cutaneous reactions from antiepileptic drugs used in the management of trigeminal neuralgia. Awareness of this uncommon but potentially fatal reaction will help to avoid the use of these drugs in patients from racial groups at high risk.
Shakib
Kaveh
K
Maxillofacial Surgery, Oral & Maxillofacial Surgery Unit, The Royal London Hospital, Whitechapel, United Kingdom. k.shakib@btconnect.co.uk
Sinanan
Marcus
M
D000927:Anticonvulsants / Q000009:adverse effects*; D044466:Asian People / Q000235:genetics; D002220:Carbamazepine / Q000009:adverse effects*; D002681:China; D004342:Drug Hypersensitivity / Q000208:ethnology / Q000235:genetics*; D005787:Gene Frequency; D015235:HLA-B Antigens / Q000235:genetics*; D059910:HLA-B15 Antigen; D006801:Humans; D018570:Risk Assessment; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000208:ethnology / Q000209:etiology* / Q000235:genetics; D014277:Trigeminal Neuralgia / Q000188:drug therapy*
D000927:Anticonvulsants; D015235:HLA-B Antigens; C483536:HLA-B*15:02 antigen; D059910:HLA-B15 Antigen; D002220:Carbamazepine